NICE has rejected Pfizer’s Ibrance breast cancer drug in first draft guidance, citing the treatment's high cost. The decision confirms the company’s fears that the drug would fare badly under ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Thanks to the new FDA policy, Ibrance has become the first and only CDK 4/6 inhibitor to be given the nod in the US for first-line treatment of men with HR+, HER2- metastatic breast cancer ...

Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback for a drug the company once called a blockbuster in the making.

Among the many promising advances in breast cancer treatment in recent years are ... affect the CDK4 protein more than the CDK6 protein. Ibrance and Kisqali affect both CDK4 and CDK6 and have ...

When you have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on ... like abemaciclib (Verzenio), palpociclib (Ibrance), and ribociclib (Kisqali).

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...